AVE SCIENCE&TECHNOLOGY CO.,LTD AVE Science&Technology CO.,LTD Stock
Equities
688067
CNE100005188
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.48 CNY | +1.86% |
|
+4.98% | -26.59% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 197M 27.26M | Sales 2023 | 200M 27.75M | Capitalization | 1.62B 224M |
|---|---|---|---|---|---|
| Net income 2022 | 18M 2.49M | Net income 2023 | 21M 2.91M | EV / Sales 2022 | 5.18 x |
| Net cash position 2022 | 255M 35.31M | Net cash position 2023 | 87.81M 12.16M | EV / Sales 2023 | 7.64 x |
| P/E ratio 2022 |
72
x | P/E ratio 2023 |
74.4
x | Employees | 531 |
| Yield 2022 |
0.53% | Yield 2023 |
-
| Free-Float | 38.01% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.86% | ||
| 1 week | +4.98% | ||
| Current month | +4.98% | ||
| 1 month | +6.39% | ||
| 3 months | +28.81% | ||
| 6 months | -27.74% | ||
| Current year | -26.59% |
1 week
16.65
17.49
1 month
13.4817.49
Current year
10.9124.50
1 year
10.9125.34
3 years
10.9145.50
5 years
10.9145.50
10 years
10.9145.50
| Managers | Title | Age | Since |
|---|---|---|---|
Jian Wen Ding
CEO | Chief Executive Officer | 67 | 94-02-28 |
Kun Xiang Long
DFI | Director of Finance/CFO | 50 | 12-01-31 |
Xiao Dong Wang
CHM | Chairman | 58 | 00-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jian Wen Ding
CEO | Chief Executive Officer | 67 | 94-02-28 |
Feng Liang Zhou
BRD | Director/Board Member | 59 | 98-05-31 |
Chang Qing Lin
BRD | Director/Board Member | 52 | 10-01-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-09 | 17.48 | +1.86% | 783,137 |
| 24-05-08 | 17.16 | -0.12% | 708,511 |
| 24-05-07 | 17.18 | +1.48% | 717,669 |
| 24-05-06 | 16.93 | +1.68% | 1,041,116 |
End-of-day quote Shanghai S.E., May 08, 2024
More quotes
AVE Science & Technology Co Ltd is a China-based company principally engaged in the research and development, production, sales and service of medical clinical laboratory analysis instruments and supporting in vitro diagnostic reagents and medical consumables. The Companyâs main products include urine formed component analyzer, urine dry chemistry analyzer, urine full item automatic analyzer, automatic stool analyzer, automatic body fluid analyzer, reproductive tract secretion analyzer, and special supporting in vitro diagnostic reagents and medical consumables and other products. The Company's products are mainly used in inspection departments of various medical and health institutions. The Company distributes its products both in the domestic market and to overseas markets.
Calendar
2024-08-27
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -26.59% | 161M | |
| -1.34% | 12.58B | |
| -1.64% | 8.51B | |
| +0.09% | 5.29B | |
| +22.42% | 5.16B | |
| -0.09% | 4.55B | |
| -52.84% | 3.04B | |
| +20.02% | 3B | |
| +31.92% | 2.17B | |
| -2.45% | 1.92B |
- Stock Market
- Equities
- 688067 Stock